China's DragonFly Lands in Europe, Reshaping Heart Care and Medtech

FRANKFURT, Germany – June 24, 2026

A small, intricate medical device designed to repair a failing human heart has just sent a large, unmistakable signal across the global technology landscape. Valgen Medtech, a company with roots in both Hangzhou, China, and Frankfurt, Germany, announced today that its DragonFly™ Transcatheter Mitral Valve Repair System has received CE mark approval in the European Union for treating Functional Mitral Regurgitation (FMR). This comes just over a year after securing the same approval for Degenerative Mitral Regurgitation (DMR), making DragonFly™ the first device of Chinese origin to be fully certified in the EU for both primary indications of a leaky mitral valve.

On the surface, this is a story of clinical progress—a new, minimally invasive tool that offers hope to high-risk heart patients. But to view it solely through a medical lens would be to miss the point. This approval is a tectonic event, a testament to the shifting structural integrity of the global medtech industry. It marks a critical milestone where Chinese innovation has not just entered, but met and mastered the labyrinthine regulatory standards of the West, challenging a market long dominated by American and European giants.

A New Lifeline for Europe's Ailing Hearts

Mitral regurgitation (MR), a condition where the heart's mitral valve fails to close properly and allows blood to leak backward, is one of the world's most common valvular diseases. It strains the heart, leading to fatigue, shortness of breath, and eventually, heart failure. The condition presents in two main forms: degenerative (DMR), where the valve leaflets themselves are damaged, and functional (FMR), where the valve is structurally normal but fails to close due to changes in the heart's shape, often as a consequence of heart failure.

For decades, the primary treatment was open-heart surgery—an effective but highly invasive procedure with significant risks, particularly for elderly patients or those with multiple comorbidities. The advent of transcatheter edge-to-edge repair (TEER), a procedure where a clip is delivered via catheter to grasp the valve leaflets and reduce the leak, created a paradigm shift. It offered a lifeline to those deemed too frail for the operating table.

Valgen Medtech’s dual approval arrives at a moment of powerful clinical consensus. In 2025, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) elevated TEER to a Class I recommendation—the highest level of endorsement—for treating select patients with FMR. This followed a similar consensus for high-risk DMR patients. The DragonFly™ system, therefore, isn't just an alternative; it is an instrument perfectly aligned with the evolving standard of care.

The clinical data underpinning the approval is robust. One-year results from the DragonFly–DMR EU Pivotal Study, presented recently at the CSI Frankfurt conference, were compelling. A remarkable 100% of high-risk, elderly patients maintained only mild or moderate MR a full year after the procedure. The primary effectiveness endpoint—a composite of freedom from death, reintervention, and significant MR—was achieved in 86.7% of patients. Procedural success was nearly universal at 97.4%, and patients' quality of life saw dramatic, sustained improvement. This is the kind of data that makes regulators and cardiologists take notice.

A Market Disrupted, A Geopolitical Shift

Beyond the clinic, the DragonFly's arrival in Europe signals a disruption in a lucrative and tightly controlled market. For years, the TEER space has been a near-duopoly dominated by two titans: Abbott with its pioneering MitraClip® system and Edwards Lifesciences with its formidable PASCAL™ device. These companies have set the standards, conducted the landmark trials, and built deep relationships with hospitals and physicians. Valgen Medtech is now the new challenger, armed with a dual-indication approval and a device that boasts unique design features, such as an elastic central mesh for better sealing and independent leaflet capture for greater precision.

This is the forensic evidence of a much larger trend. China is methodically executing a strategic pivot from being the world's factory to becoming one of its premier innovation hubs, a core tenet of its 'Made in China 2025' industrial policy. The success of Valgen Medtech, a company founded only in 2015, is a case study in this transformation. Obtaining a CE mark under the EU's notoriously stringent Medical Device Regulation (MDR) is a monumental task. It requires unimpeachable clinical evidence, transparent technical files, and a bulletproof quality management system. For a Chinese firm to achieve this for a high-risk Class III device not once, but twice, dismantles outdated notions about the quality and rigor of Chinese R&D.

It demonstrates a capacity to navigate complex global systems and a willingness to invest heavily in the long, arduous process of validation. With over 600 patents applied for and a large, dedicated research team, Valgen Medtech is not an anomaly but an avatar of a new generation of Chinese technology firms built for global competition.

The 'Tool Box' Strategy

Valgen Medtech’s ambition does not end with the mitral valve. The company's stated strategy is to build a comprehensive 'Tool Box' of interventional devices for all forms of structural heart disease. The DragonFly™ is the flagship, but it is supported by a suite of other approved devices for guiding catheters and performing related procedures. This holistic approach suggests a long-term vision to become an indispensable partner for interventional cardiology departments.

The company has already laid the groundwork for this global push, securing approvals and beginning commercial sales in 15 countries across Latin America and Southeast Asia. The EU approval, however, is the crown jewel—the key that unlocks the world's most sophisticated and valuable healthcare markets. It validates the technology not just for European patients, but for regulators and physicians worldwide who look to the CE mark as a benchmark for safety and efficacy.

The approval of the DragonFly™ system is more than a press release. It is a data point indicating a fundamental realignment in the systems that govern global health and technology. It shows how clinical need, regulatory frameworks, and national industrial strategy can converge to create new realities on the ground—or in this case, inside the beating heart of a patient. A new lifeline for patients has become a new fault line in the competitive landscape, and the tremors are only just beginning.